Tomomi Kaneko

发表

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer

H. Lenz, M. Pishvaian, P. Wilson, 2016, Molecular Cancer Therapeutics.

Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.

A. Shimatsu, S. Tahara, M. Murakami, 2017, Endocrine journal.

A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.

Tomoaki Tanaka, A. Shimatsu, S. Midorikawa, 2020, Endocrine journal.

Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.

G. Scagliotti, R. Plummer, Michael Thomas, 2015, Clinical lung cancer.

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.